Back to Journals » Vascular Health and Risk Management » Volume 13

Original Research

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

      
Total article views   HTML views PDF downloads Totals
6,873 Dovepress* 5,932+ 1,594 7,526
PubMed Central* 941 278 1,219
Totals 6,873 1,872 8,745
*Since 6 July 2017

View citations on PubMed Central and Google Scholar